Is Calliditas Therapeutics AB (publ) (CALTX.ST) a Buy, Sell, or Hold?
STO : CALTX.ST
Calliditas Therapeutics AB (publ)
$208 SEK
$1.8 (0.87%)
- Volume
- 45.08K
- Average Volume
- 103.32K
- Market Capitalization
- $11.24B
- P/E Ratio
- -23.94
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $208.80
- Year Low
- $80.80
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.13
Company Overview
STO
Renee Aguiar-Lucander
Biotechnology
Healthcare
CALTX.ST
222
SE
SEK
Liquidity Metrics
2.92
3.13
3.08
2.39
0.00
Sales & Valuation
$1.21B
9.31
33.34
-25.12
-8.34
Profitability
-$8.69
-$466.18M
-38.63%
-37.87%
-84.68%
-24.53%
P/E Metrics
-23.94
0.41
0.41
Analyst Price Target & Rating
0/5
3 Analysts
%
Financial Health Scores
4.85
2/9
$724.69M
$1.75B
$1.64B
-$357.42M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Teona Johnson | Head of US Marketing |
| Fredrik Johansson | Chief Financial Officer |
| Ann-Kristin Myde | Head of Clinical Development & Vice President of Project Management |
| Asa Hillsten | Head of IR & Sustainability |
| Renee Aguiar-Lucander | Chief Executive Officer |
| Sandra Frithiof | Vice President of Human Resources |
| Richard S. Philipson | Chief Medical Officer |
| Lars Stubberud | Vice President of Technical Operations |
| Brian Gorman | Group General Counsel |
| David Ferraro | Head of US Sales |
Poll Results
No votes yet today — be the first to share your view!
About Calliditas Therapeutics AB (publ) (STO:CALTX.ST) Stock
Calliditas Therapeutics AB is a clinical-stage biopharmaceutical company, established in Stockholm, Sweden in 2004. Its core business is to discover, develop, and commercialize pharmaceutical treatments for rare diseases, initially concentrating on conditions affecting the kidneys and liver. The company's portfolio features Nefecon, an oral budesonide immunosuppressant designed to treat immunoglobulin A nephropathy, an autoimmune renal disease. A leading candidate, Setanaxib, a NOX inhibitor, is currently in Phase 2b/3 trials for primary biliary cholangitis, and Phase 2 trials for squamous cell carcinoma of the head and neck, idiopathic pulmonary fibrosis, and type 1 diabetic kidney disease. Additionally, Calliditas develops Budenofalk 3 mg oral capsules for the management of autoimmune he ... patitis.
Frequently Asked Questions
-
What is the current Calliditas Therapeutics AB (publ) (CALTX.ST) stock price?
-
Calliditas Therapeutics AB (publ)(STO:CALTX.ST) stock price is $208 in the last trading session. During the trading session, CALTX.ST stock reached the peak price of $208.8 while $80.8 was the lowest point it dropped to. The percentage change in CALTX.ST stock occurred in the recent session was 0.87% while the dollar amount for the price change in CALTX.ST stock was $1.8.
-
CALTX.ST's industry and sector of operation?
-
The STO listed CALTX.ST is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CALTX.ST?
-
Teona Johnson | Head of US Marketing
Fredrik Johansson | Chief Financial Officer
Ann-Kristin Myde | Head of Clinical Development & Vice President of Project Management
Asa Hillsten | Head of IR & Sustainability
Renee Aguiar-Lucander | Chief Executive Officer -
How many employees does CALTX.ST have?
-
Number of CALTX.ST employees currently stands at 222. CALTX.ST operates from Kungsbron 1, D5, Stockholm, None 111 22, SE.
-
Link for CALTX.ST official website?
-
Official Website of CALTX.ST is: https://www.calliditas.se
-
How do I contact CALTX.ST?
-
CALTX.ST could be contacted at phone #46 84 11 30 05 and can also be accessed through its website. CALTX.ST operates from Kungsbron 1, D5, Stockholm, None 111 22, SE.
-
How many shares of CALTX.ST are traded daily?
-
The average number of CALTX.ST shares traded daily for last 3 months was 103.32K.
-
What is the market cap of CALTX.ST currently?
-
The market value of CALTX.ST currently stands at $11.24B with its latest stock price at $208